Compare Neurocrine Biosciences Inc (NBIX) vs Riot Platforms Inc (RIOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Riot Platforms Inc — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Riot Platforms Inc trades at $21.52 (market cap $7.53B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.3× Riot Platforms Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Riot Platforms Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | RIOT | |
|---|---|---|
Market Cap | $17.40B | $7.53B |
Sector | Health | Technology |
52-Week High | $180.55 | $28.67 |
52-Week Low | $123.10 | $11.03 |
Enterprise Value | $16.49B | $8.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% today, with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with Q1 2026 EPS of $1.94 beating expectations by 59%, revenue growth to $3.1B in 2026, and net income margin expanding to 21.55%. Recent news highlights executive appointments and positive clinical trial updates for crinecerfont, supporting growth prospects.
Outlook remains positive with 86% analyst buy ratings and a $196.08 consensus price target implying 13% upside. Key risks include execution of pipeline developments and integration of acquisitions. The stock's valuation at P/E 26.62 appears reasonable given earnings growth trajectory and strong profitability metrics.
RIOT trades at $19.90, up 8.98% in the past 24 hours, but faces a bearish technical signal despite strong analyst support. The company reported a significant net loss of $663.18 million in 2025 with negative profit margins, though revenue reached $647.44 million. Recent news highlights volatility and strategic partnerships in data center development.
Wall Street remains overwhelmingly bullish with 94% buy ratings and a $28.67 price target, but fundamental weaknesses and cash flow challenges present substantial risks. The stock's outlook depends on improving profitability and successful execution of its business expansion amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →
